-
1
-
-
27744587040
-
Clinical trial design to evaluate the effects of drugs on cardiac repolarization: Current state of the art
-
Camm AJ. Clinical trial design to evaluate the effects of drugs on cardiac repolarization: current state of the art. Heart Rhythm 2005; 2 (2 Suppl.): S23-9.
-
(2005)
Heart Rhythm
, vol.2
, Issue.2 SUPPL.
-
-
Camm, A.J.1
-
2
-
-
77949415660
-
-
ICH E14 The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs. International Conference on Harmonisation Step 4 Guideline, EMEA, CHMP/ICH/2/04. 25-5-2005.
-
ICH E14 The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs. International Conference on Harmonisation Step 4 Guideline, EMEA, CHMP/ICH/2/04. 25-5-2005.
-
-
-
-
3
-
-
0035293881
-
Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes
-
Owens RC Jr. Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes. Pharmacotherapy 2001; 21: 301-19.
-
(2001)
Pharmacotherapy
, vol.21
, pp. 301-319
-
-
Owens Jr., R.C.1
-
5
-
-
0034525584
-
Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects
-
Demolis JL, Kubitza D, Tenneze L, Funck-Brentano C. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. Clin Pharmacol Ther 2000; 68: 658-66.
-
(2000)
Clin Pharmacol Ther
, vol.68
, pp. 658-666
-
-
Demolis, J.L.1
Kubitza, D.2
Tenneze, L.3
Funck-Brentano, C.4
-
6
-
-
0035170062
-
Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG
-
Kang J, Wang L, Chen XL, Triggle DJ, Rampe D. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol 2001; 59: 122-6.
-
(2001)
Mol Pharmacol
, vol.59
, pp. 122-126
-
-
Kang, J.1
Wang, L.2
Chen, X.L.3
Triggle, D.J.4
Rampe, D.5
-
7
-
-
27744502903
-
The assessment of QT/QTc interval prolongation in clinical trials: A regulatory perspective
-
Strnadova C. The assessment of QT/QTc interval prolongation in clinical trials: a regulatory perspective. Drug Information J 2005; 39: 407-33.
-
(2005)
Drug Information J
, vol.39
, pp. 407-433
-
-
Strnadova, C.1
-
8
-
-
0842284660
-
A definitive or thorough phase 1 QT ECG trial as a requirement for drug safety assessment
-
Morganroth J. A definitive or thorough phase 1 QT ECG trial as a requirement for drug safety assessment. J Electrocardiol 2004; 37: 25-9.
-
(2004)
J Electrocardiol
, vol.37
, pp. 25-29
-
-
Morganroth, J.1
-
9
-
-
1942476132
-
Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings
-
Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J. Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings. J Clin Pharmacol 2004; 44: 464-73.
-
(2004)
J Clin Pharmacol
, vol.44
, pp. 464-473
-
-
Noel, G.J.1
Goodman, D.B.2
Chien, S.3
Solanki, B.4
Padmanabhan, M.5
Natarajan, J.6
-
10
-
-
0037385205
-
Effects of three fluoroquinolones on QT interval in healthy adults after single doses
-
Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther 2003; 73: 292-303.
-
(2003)
Clin Pharmacol Ther
, vol.73
, pp. 292-303
-
-
Noel, G.J.1
Natarajan, J.2
Chien, S.3
Hunt, T.L.4
Goodman, D.B.5
Abels, R.6
-
11
-
-
33644990125
-
Effects of three fluoroquinolones on QT analysis after standard treatment courses
-
Tsikouris JP, Peeters MJ, Cox CD, Meyerrose GE, Seifert CF. Effects of three fluoroquinolones on QT analysis after standard treatment courses. Ann Noninvasive Electrocardiol 2006; 11: 52-6.
-
(2006)
Ann Noninvasive Electrocardiol
, vol.11
, pp. 52-56
-
-
Tsikouris, J.P.1
Peeters, M.J.2
Cox, C.D.3
Meyerrose, G.E.4
Seifert, C.F.5
-
12
-
-
33644861943
-
Effect of ciprofloxacin and levofloxacin on the QT interval: Is this a significant 'clinical' event?
-
Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B. Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant 'clinical' event? South Med J 2006; 99: 52-6.
-
(2006)
South Med J
, vol.99
, pp. 52-56
-
-
Makaryus, A.N.1
Byrns, K.2
Makaryus, M.N.3
Natarajan, U.4
Singer, C.5
Goldner, B.6
-
13
-
-
27744502903
-
The assessment of QT/QTc interval prolongation in clinical trials: A regulatory perspective
-
Strnadova C. The assessment of QT/QTc interval prolongation in clinical trials: a regulatory perspective. Drug Information J 2005; 39: 407-33.
-
(2005)
Drug Information J
, vol.39
, pp. 407-433
-
-
Strnadova, C.1
-
14
-
-
11144273910
-
Sample size, power calculations, and their implications for the cost of thorough studies of drug induced QT interval prolongation
-
Malik M, Hnatkova K, Batchvarov V, Gang Y, Smetana P, Camm AJ. Sample size, power calculations, and their implications for the cost of thorough studies of drug induced QT interval prolongation. Pacing Clin Electrophysiol 2004; 27: 1659-69.
-
(2004)
Pacing Clin Electrophysiol
, vol.27
, pp. 1659-1669
-
-
Malik, M.1
Hnatkova, K.2
Batchvarov, V.3
Gang, Y.4
Smetana, P.5
Camm, A.J.6
-
15
-
-
0031903272
-
Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects
-
Stass H, Dalhoff A, Kubitza D, Schühly U. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother 1998; 42: 2060-5.
-
(1998)
Antimicrob Agents Chemother
, vol.42
, pp. 2060-2065
-
-
Stass, H.1
Dalhoff, A.2
Kubitza, D.3
Schühly, U.4
-
16
-
-
0032898860
-
Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man
-
Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 1999; 43 (Suppl. B): 83-90.
-
(1999)
J Antimicrob Chemother
, vol.43
, Issue.SUPPL. B
, pp. 83-90
-
-
Stass, H.1
Kubitza, D.2
-
17
-
-
0035054726
-
Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials
-
Aminimanizani A, Beringer P, Jelliffe R. Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials. Clin Pharmacokinet 2001; 40: 169-87.
-
(2001)
Clin Pharmacokinet
, vol.40
, pp. 169-187
-
-
Aminimanizani, A.1
Beringer, P.2
Jelliffe, R.3
-
18
-
-
0032729635
-
Pharmacokinetics of a once-daily oral dose of moxifloxacin (bay 12-8039), a new enantiomerically pure 8-methoxy quinolone
-
Sullivan JT, Woodruff M, Lettieri J, Agarwal V, Krol GJ, Leese PT, Watson S, Heller AH. Pharmacokinetics of a once-daily oral dose of moxifloxacin (bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. Antimicrob Agents Chemother 1999; 43: 2793-7.
-
(1999)
Antimicrob Agents Chemother
, vol.43
, pp. 2793-2797
-
-
Sullivan, J.T.1
Woodruff, M.2
Lettieri, J.3
Agarwal, V.4
Krol, G.J.5
Leese, P.T.6
Watson, S.7
Heller, A.H.8
-
19
-
-
0030790098
-
Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects
-
Chien SC, Chow AT, Natarajan J, Williams RR, Wong FA, Rogge MC, Nayak RK. Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects. Antimicrob Agents Chemother 1997; 41: 1562-5.
-
(1997)
Antimicrob Agents Chemother
, vol.41
, pp. 1562-1565
-
-
Chien, S.C.1
Chow, A.T.2
Natarajan, J.3
Williams, R.R.4
Wong, F.A.5
Rogge, M.C.6
Nayak, R.K.7
-
20
-
-
0033802359
-
Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers
-
Lubasch A, Keller I, Borner K, Koeppe P, Lode H. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 2000; 44: 2600-3.
-
(2000)
Antimicrob Agents Chemother
, vol.44
, pp. 2600-2603
-
-
Lubasch, A.1
Keller, I.2
Borner, K.3
Koeppe, P.4
Lode, H.5
-
21
-
-
77949390566
-
-
ICH E14 The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs. International Conference on Harmonisation. E14 Implementation and Working Group, Questions and Answers. 4-6-2008.
-
ICH E14 The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs. International Conference on Harmonisation. E14 Implementation and Working Group, Questions and Answers. 4-6-2008.
-
-
-
-
22
-
-
49549113387
-
Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects
-
Epub Jul 23
-
Dixon R, Job S, Oliver R, Tompson D, Wright JG, Maltby K, Lorch U, Taubel J. Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects. Br J Clin Pharmacol 2008; 66: 396-404. Epub 2008 Jul 23.
-
(2008)
Br J Clin Pharmacol 2008
, vol.66
, pp. 396-404
-
-
Dixon, R.1
Job, S.2
Oliver, R.3
Tompson, D.4
Wright, J.G.5
Maltby, K.6
Lorch, U.7
Taubel, J.8
-
23
-
-
35248869253
-
Levocetirizine does not prolong the QT/QTc interval in healthy subjects: Results from a thorough QT study
-
Hulhoven R, Rosillon D, Letiexhe M, Meeus MA, Daoust A, Stockis A. Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study. Eur J Clin Pharmacol 2007; 63: 1011-7.
-
(2007)
Eur J Clin Pharmacol
, vol.63
, pp. 1011-1017
-
-
Hulhoven, R.1
Rosillon, D.2
Letiexhe, M.3
Meeus, M.A.4
Daoust, A.5
Stockis, A.6
-
24
-
-
33847632522
-
Thorough QT study with recommended and supratherapeutic doses of tolterodine
-
Malhotra BK, Glue P, Sweeney K, Anziano R, Mancuso J, Wicker P. Thorough QT study with recommended and supratherapeutic doses of tolterodine. Clin Pharmacol Ther 2007; 81: 377-85.
-
(2007)
Clin Pharmacol Ther
, vol.81
, pp. 377-385
-
-
Malhotra, B.K.1
Glue, P.2
Sweeney, K.3
Anziano, R.4
Mancuso, J.5
Wicker, P.6
-
25
-
-
44649109705
-
Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers
-
Peeters M, Janssen K, Kakuda TN, Schöller-Gyüre M, Lachaert R, Hoetelmans RM, Woodfall B, De Smedt G. Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers. Ann Pharmacother 2008; 42: 757-65.
-
(2008)
Ann Pharmacother
, vol.42
, pp. 757-765
-
-
Peeters, M.1
Janssen, K.2
Kakuda, T.N.3
Schöller-Gyüre, M.4
Lachaert, R.5
Hoetelmans, R.M.6
Woodfall, B.7
De Smedt, G.8
-
26
-
-
50349099149
-
The effect of moxifloxacin on QTc and implications for the design of thorough QT studies
-
Bloomfield D, Kost J, Ghosh K, Hreniuk D, Hickey L, Guitierrez M, Gottesdiener K, Wagner J. The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin Pharmacol Ther 2008; 84: 475-80.
-
(2008)
Clin Pharmacol Ther
, vol.84
, pp. 475-480
-
-
Bloomfield, D.1
Kost, J.2
Ghosh, K.3
Hreniuk, D.4
Hickey, L.5
Guitierrez, M.6
Gottesdiener, K.7
Wagner, J.8
-
27
-
-
40549135640
-
Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects
-
Davis JD, Hackman F, Layton G, Higgins T, Sudworth D, Weissgerber G. Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects. Br J Clin Pharmacol 2008; 65 (Suppl. 1): 68-75.
-
(2008)
Br J Clin Pharmacol
, vol.65
, Issue.SUPPL. 1
, pp. 68-75
-
-
Davis, J.D.1
Hackman, F.2
Layton, G.3
Higgins, T.4
Sudworth, D.5
Weissgerber, G.6
-
28
-
-
41549161099
-
Effect of levetiracetam on cardiac repolarization in healthy subjects: A single-dose, randomized, placebo- and active-controlled, four-way crossover study
-
Hulhoven R, Rosillon D, Bridson WE, Meeus MA, Salas E, Stockis A. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study. Clin Ther 2008; 30: 260-70.
-
(2008)
Clin Ther
, vol.30
, pp. 260-270
-
-
Hulhoven, R.1
Rosillon, D.2
Bridson, W.E.3
Meeus, M.A.4
Salas, E.5
Stockis, A.6
-
29
-
-
37549043173
-
Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: A possible role as CYP3A inhibitor in thorough QTc studies
-
Epub Jun 20
-
Sarapa N, Nickens DJ, Raber SR, Reynolds RR, Amantea MA. Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: a possible role as CYP3A inhibitor in thorough QTc studies. Clin Pharmacol Ther 2008; 83: 153-9. Epub 2007 Jun 20.
-
(2007)
Clin Pharmacol Ther 2008
, vol.83
, pp. 153-159
-
-
Sarapa, N.1
Nickens, D.J.2
Raber, S.R.3
Reynolds, R.R.4
Amantea, M.A.5
-
30
-
-
1942476132
-
Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings
-
Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J. Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings. J Clin Pharmacol 2004; 44: 464-73.
-
(2004)
J Clin Pharmacol
, vol.44
, pp. 464-473
-
-
Noel, G.J.1
Goodman, D.B.2
Chien, S.3
Solanki, B.4
Padmanabhan, M.5
Natarajan, J.6
|